Zene (株式会社Zene)
Chiyoda City, Japan
Zene is a startup that determines "lifetime invariant disease risk" through individual genetic analysis and supports countermeasures. The difference between the company's genetic analysis service and conventional genetic testing is that it uses a "polygenic risk score method" that comprehensively analyzes the entire genomic information. Instead of the conventional method of dividing several genes by type and providing the proportion of diseased people, AI is used to comprehensively test more gene information, so the analysis accuracy will be higher.
Company Info
- Founded
- 2020
- Website
- www.zene.co.jp/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Zene (株式会社Zene)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.